Key Highlights
- Loss per share was USD 1.14 against an estimate of a USD 0.95 loss.
- Revenue was USD 722 thousand against an estimate of USD 920 thousand.
- Net loss was USD 8.66 million, compared with USD 4.42 million.
- Cash and cash equivalents were USD 879 thousand at September 30.
Cerenome (NASDAQ:CNSY) reported a third quarter 2026 loss per share of USD 1.14, against an estimate of a USD 0.95 loss and a USD 1.03 loss in the third quarter of 2025. Revenue was USD 722 thousand, against an estimate of USD 920.33 thousand and USD 1.40 million in the prior-year quarter.
The net loss was USD 8.66 million, compared with USD 4.42 million, and the operating loss was USD 7.46 million, compared with USD 4.48 million. Amounts in the filing are presented in thousands.
Operating Expenses
Research and development expenses were USD 2.11 million, compared with USD 2.44 million, and selling, general and administrative expenses were USD 5.16 million, compared with USD 3.44 million. Cost of revenue was USD 912 thousand, with none in the prior-year quarter. Total operating expenses were USD 8.18 million, compared with USD 5.88 million.
Interest income was USD 119 thousand, compared with USD 59 thousand, and interest expense was USD 14 thousand. The filing also reports financing expenses of USD 1.62 million for the quarter.
Nine-Month Results
For the nine months ended September 30, 2026, revenue was USD 2.16 million, compared with USD 3.85 million, and the net loss was USD 24.61 million, compared with USD 16.67 million. The loss per share was USD 3.50, compared with USD 7.21.
Research and development expenses for the nine months were USD 9.24 million, compared with USD 5.44 million, and selling, general and administrative expenses were USD 15.64 million, compared with USD 7.96 million. Total operating expenses were USD 25.79 million, compared with USD 13.40 million, and the operating loss was USD 23.63 million, compared with USD 9.56 million.
Revenue, Cash Flow and Balance Sheet
The filing states that grant revenue represents the share of costs incurred that is funded by the Cancer Prevention and Research Institute of Texas for the company's rhenium-186 program. Net cash used in Operating Activities for the nine months was USD 21.04 million, compared with USD 14.52 million.
Cash and cash equivalents were USD 879 thousand, compared with USD 4.26 million at the prior Balance Sheet date, and restricted cash and cash equivalents were zero, compared with USD 4.50 million. Accounts receivable, net, were USD 722 thousand. Total Assets were USD 12.20 million, compared with USD 16.33 million, and total liabilities were USD 13.12 million, compared with USD 12.33 million.
The filing states that during the nine months ended September 30, 2026 the company paid the March 2025 private Placement purchasers USD 4.5 million to fully satisfy the investor Liability owed under the modified letter agreement, and that 272,821 shares were returned and cancelled under its terms. It states that, as a result, the restriction lapsed on USD 4.5 million of restricted cash and cash equivalents, and that adjustments for the Reverse Stock Split were made retroactively for all periods presented.
Cerenome Q3 2026 Earnings: Key Takeaways
Cerenome reported a third quarter 2026 loss per share of USD 1.14, revenue of USD 722 thousand and a net loss of USD 8.66 million. Cash and cash equivalents were USD 879 thousand at September 30, 2026.






Please wait processing your request...